DK1560575T3 - 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf - Google Patents
3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer derafInfo
- Publication number
- DK1560575T3 DK1560575T3 DK03767529T DK03767529T DK1560575T3 DK 1560575 T3 DK1560575 T3 DK 1560575T3 DK 03767529 T DK03767529 T DK 03767529T DK 03767529 T DK03767529 T DK 03767529T DK 1560575 T3 DK1560575 T3 DK 1560575T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutical formulations
- thyromimetic
- triiodothyronine
- triiodothyronine sulfate
- sulfate
- Prior art date
Links
- XBQYQXVJBNDCGY-LBPRGKRZSA-N 3,3',5-triiodo-L-thyronine sulfate Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(OS(O)(=O)=O)C(I)=C1 XBQYQXVJBNDCGY-LBPRGKRZSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000929 thyromimetic effect Effects 0.000 title abstract 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229940034208 thyroxine Drugs 0.000 abstract 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/76—Chemiluminescence; Bioluminescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Plasma & Fusion (AREA)
- Electrochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20022394 ITMI20022394A1 (it) | 2002-11-13 | 2002-11-13 | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| PCT/EP2003/012584 WO2004043452A1 (en) | 2002-11-13 | 2003-11-11 | 3,5,3’-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1560575T3 true DK1560575T3 (da) | 2007-01-29 |
Family
ID=32310157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03767529T DK1560575T3 (da) | 2002-11-13 | 2003-11-11 | 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9012438B2 (da) |
| EP (2) | EP1560575B1 (da) |
| JP (2) | JP5301074B2 (da) |
| CN (2) | CN101406467A (da) |
| AT (1) | ATE340570T1 (da) |
| AU (1) | AU2003292006A1 (da) |
| CY (1) | CY1107312T1 (da) |
| DE (1) | DE60308718T2 (da) |
| DK (1) | DK1560575T3 (da) |
| ES (1) | ES2273045T3 (da) |
| IT (1) | ITMI20022394A1 (da) |
| PT (1) | PT1560575E (da) |
| WO (1) | WO2004043452A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20110713A1 (it) * | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| GB0525461D0 (en) * | 2005-12-15 | 2006-01-25 | Archimedes Dev Ltd | Pharmaceutical compositions |
| US20120178813A1 (en) | 2011-01-12 | 2012-07-12 | Thetis Pharmaceuticals Llc | Lipid-lowering antidiabetic agent |
| DK2694471T3 (da) * | 2011-04-08 | 2017-11-13 | Bracco Imaging Spa | Fremgangsmåde til fremstilling af et sulfateret derivat af 3,5-diiod-o-[3-iodphenyl]-l-tyrosin |
| CN102507919A (zh) * | 2011-11-08 | 2012-06-20 | 江苏省原子医学研究所 | 一种标记3,3’-二碘甲腺氨酸硫酸化物的方法及检测试剂盒 |
| WO2015171516A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
| US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
| MX2016016830A (es) | 2014-06-18 | 2017-07-07 | Thetis Pharmaceuticals Llc | Complejos de aminoacidos minerales de agentes activos. |
| DK3454907T3 (da) | 2016-06-03 | 2020-10-19 | Thetis Pharmaceuticals Llc | Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation |
| JP6968603B2 (ja) * | 2017-07-10 | 2021-11-17 | キヤノン株式会社 | 画像形成装置、画像形成方法、プログラム |
| JP2021531478A (ja) * | 2018-07-13 | 2021-11-18 | エーギルバイオ エービー | 甲状腺機能障害の診断のためのバイオセンサー |
| WO2024129551A1 (en) * | 2022-12-16 | 2024-06-20 | Merck Sharp & Dohme Llc | Solid dosage form of a small molecule antiviral and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2993928A (en) | 1957-01-15 | 1961-07-25 | Glaxo Lab Ltd | Preparation of triiodothyronine |
| US2970165A (en) | 1957-10-01 | 1961-01-31 | Warner Lambert Pharmaceutical | Sulfate compounds |
| US3313839A (en) | 1963-07-01 | 1967-04-11 | Gen Aniline & Film Corp | Preparation of sulfate esters by the reaction of chlorosulfonic acid with alkoxylated alkyl phenols |
| US4031622A (en) * | 1975-10-28 | 1977-06-28 | Wells Manufacturing Corporation | Portable power driven implement |
| US4254095A (en) * | 1978-04-27 | 1981-03-03 | Research Corporation | Radioimmunoassay for erythropoietin |
| JPH07116031B2 (ja) * | 1986-09-24 | 1995-12-13 | 株式会社アドバンス | 制癌剤 |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| US5158978A (en) | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
| EP0466909B1 (en) | 1990-02-05 | 1995-06-28 | British Technology Group (Usa) Incorporated | Thyroid hormone for cardiac treatment |
| US5272078A (en) * | 1991-01-29 | 1993-12-21 | Brigham And Women's Hospital | CDNA encoding the type I iodothyronine 5'deiodinase |
| US6498037B1 (en) | 1991-03-04 | 2002-12-24 | Bayer Corporation | Method of handling reagents in a random access protocol |
| US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
| NO924985L (no) | 1991-12-30 | 1993-07-01 | Akzo Nv | Thyroaktiv blanding med vedvarende frigjoering |
| KR950010051Y1 (ko) | 1993-10-15 | 1995-11-25 | 이해섭 | 휴대용 절첩테이블 |
| GB9401892D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
| DE19541128C2 (de) | 1995-10-27 | 1997-11-27 | Henning Berlin Gmbh & Co | Stabilisierte schilddrüsenhormonhaltige Arzneimittel |
| MXPA98003802A (es) | 1995-11-14 | 2005-04-29 | Abbott Gmbh & Co Kg | Preparaciones de hormona tiroidea estabilizadas ymetodos para fabricar las mismas. |
| JP2002504689A (ja) | 1998-02-18 | 2002-02-12 | デイド・ベーリング・インコーポレイテッド | 複数の検体の検出において使用するための化学ルミネセンス組成物 |
| DE19821625C1 (de) | 1998-05-15 | 2000-01-05 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| US6599942B1 (en) * | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
| US6740680B1 (en) * | 1999-04-26 | 2004-05-25 | Becton Pharma, Inc. | Pharmaceutical compositions to tetrac and methods of use thereof |
| US6664291B2 (en) * | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| US20020076827A1 (en) * | 2000-07-26 | 2002-06-20 | Salhanick Hilton A. | Methods for diagnosing thyroid conditions and for monitoring thyroxine therapy |
| US7163918B2 (en) * | 2000-08-22 | 2007-01-16 | New River Pharmaceuticals Inc. | Iodothyronine compositions |
| US6855333B1 (en) | 2000-10-03 | 2005-02-15 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid thyroid drug formulations |
| US6979462B1 (en) | 2000-10-03 | 2005-12-27 | Mutual Pharmaceutical Co., Inc. | Stabilization of solid drug formulations |
| US20030224047A1 (en) | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| BR0207297A (pt) | 2001-02-15 | 2005-04-19 | King Pharmaceuticals Inc | Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo |
| ITMI20011401A1 (it) | 2001-07-02 | 2003-01-02 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei |
| DE10136615A1 (de) | 2001-07-17 | 2003-02-06 | Berlin Chemie Ag | Schilddrüsentherapeutika |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US20030195253A1 (en) | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20030099699A1 (en) | 2001-11-13 | 2003-05-29 | Hanshew Dwight D. | Storage stable thyroxine active drug formulations and methods for their production |
| ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
| ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
| ITMI20022777A1 (it) | 2002-12-27 | 2004-06-28 | Altergon Sa | Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento. |
| US20040156893A1 (en) | 2003-02-11 | 2004-08-12 | Irwin Klein | Method for treating hypothyroidism |
| US8293272B2 (en) | 2003-05-02 | 2012-10-23 | Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. | Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts |
| DK1622587T3 (da) | 2003-05-02 | 2010-08-23 | Globopharm Pharmazeutische Pro | Fast farmaceutisk præparat indeholdende levothyroxin- og/eller liothyroninsalte |
| GB0316206D0 (en) | 2003-07-10 | 2003-08-13 | Glaxo Group Ltd | Pharmaceutical formulation |
| PT2801355E (pt) | 2004-10-08 | 2015-09-18 | Forward Pharma As | Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico |
| AU2007267612A1 (en) | 2006-05-26 | 2007-12-06 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted carboxylic acid compounds |
| PT1958617E (pt) | 2007-02-14 | 2010-10-28 | Lesvi Laboratorios Sl | Composições farmacêuticas contendo fumarato de quetiapina |
| US20100136109A1 (en) | 2007-04-23 | 2010-06-03 | Richard Ross | Sustained release |
| WO2008140459A1 (en) | 2007-05-16 | 2008-11-20 | Fmc Corporation | Solid form |
| EP1992341A1 (en) | 2007-05-16 | 2008-11-19 | Université Joseph Fourier | New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use |
| FR2931359B1 (fr) | 2008-05-20 | 2012-12-21 | Menvielle Bourg Fabienne Joanny | Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice |
| ES2730678T3 (es) | 2009-04-01 | 2019-11-12 | Bial Portela & Ca Sa | Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas |
| CN102259831A (zh) | 2010-05-27 | 2011-11-30 | 清华大学 | 三维纳米结构阵列 |
-
2002
- 2002-11-13 IT ITMI20022394 patent/ITMI20022394A1/it unknown
-
2003
- 2003-11-11 AU AU2003292006A patent/AU2003292006A1/en not_active Abandoned
- 2003-11-11 CN CNA2008101357627A patent/CN101406467A/zh active Pending
- 2003-11-11 CN CNA2003801030574A patent/CN1711079A/zh active Pending
- 2003-11-11 EP EP03767529A patent/EP1560575B1/en not_active Expired - Lifetime
- 2003-11-11 PT PT03767529T patent/PT1560575E/pt unknown
- 2003-11-11 WO PCT/EP2003/012584 patent/WO2004043452A1/en active IP Right Grant
- 2003-11-11 US US10/532,447 patent/US9012438B2/en not_active Expired - Fee Related
- 2003-11-11 DE DE2003608718 patent/DE60308718T2/de not_active Expired - Lifetime
- 2003-11-11 AT AT03767529T patent/ATE340570T1/de active
- 2003-11-11 ES ES03767529T patent/ES2273045T3/es not_active Expired - Lifetime
- 2003-11-11 DK DK03767529T patent/DK1560575T3/da active
- 2003-11-11 EP EP20060117480 patent/EP1767202A1/en not_active Withdrawn
- 2003-11-11 JP JP2004550983A patent/JP5301074B2/ja not_active Expired - Fee Related
-
2006
- 2006-11-14 CY CY061101656T patent/CY1107312T1/el unknown
-
2010
- 2010-12-24 JP JP2010288189A patent/JP2011102306A/ja active Pending
-
2011
- 2011-04-08 US US13/083,047 patent/US20110245342A1/en not_active Abandoned
-
2013
- 2013-01-31 US US13/755,279 patent/US9044441B2/en active Active
- 2013-06-13 US US13/916,710 patent/US9468619B2/en active Active
-
2016
- 2016-09-21 US US15/271,355 patent/US10238615B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE60308718D1 (de) | 2006-11-09 |
| ES2273045T3 (es) | 2007-05-01 |
| EP1560575B1 (en) | 2006-09-27 |
| US20170007563A1 (en) | 2017-01-12 |
| AU2003292006A1 (en) | 2004-06-03 |
| JP5301074B2 (ja) | 2013-09-25 |
| PT1560575E (pt) | 2007-01-31 |
| EP1560575A1 (en) | 2005-08-10 |
| CY1107312T1 (el) | 2012-11-21 |
| US10238615B2 (en) | 2019-03-26 |
| US9012438B2 (en) | 2015-04-21 |
| US9044441B2 (en) | 2015-06-02 |
| EP1767202A1 (en) | 2007-03-28 |
| US20130281536A1 (en) | 2013-10-24 |
| JP2006508956A (ja) | 2006-03-16 |
| ATE340570T1 (de) | 2006-10-15 |
| CN101406467A (zh) | 2009-04-15 |
| CN1711079A (zh) | 2005-12-21 |
| US20050272816A1 (en) | 2005-12-08 |
| WO2004043452A1 (en) | 2004-05-27 |
| US9468619B2 (en) | 2016-10-18 |
| DE60308718T2 (de) | 2007-08-02 |
| JP2011102306A (ja) | 2011-05-26 |
| ITMI20022394A1 (it) | 2004-05-14 |
| US20110245342A1 (en) | 2011-10-06 |
| US20130146502A1 (en) | 2013-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107312T1 (el) | Θειικη 3,5,3’-τριιωδοθυρονινη σαν θυρεοειδο-μιμητικος παραγοντας και φαρμακευτικα σκευασματα της | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| BR0313371A (pt) | Composto, uso de um composto e método de tratamento de doença | |
| ECSP045081A (es) | Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados | |
| CY1111867T1 (el) | Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη | |
| CY1114979T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν ορνιθινη και φαινυλοξικο ή φαινυλοβουτυρικο για αντιμετωπιση ηπατικης εγκεφαλοπαθειας | |
| ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
| HK1070305A1 (en) | Pharmaceutical composition comprising gabapentin or an analogue thereof and an sg(a)-aminoamide and its analgesic use | |
| DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
| HRP20050439B1 (en) | New use of dextran sulfate | |
| CY1110130T1 (el) | Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α. | |
| BR0112770A (pt) | Agentes herbicidas | |
| BR0312683A (pt) | Cápsulas de higiene oral | |
| DE60314722D1 (de) | Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall | |
| BR0314689A (pt) | Brinquedo para várias pessoas, e, brinquedo | |
| BRPI0511125A (pt) | usos de ácido 5,6,7-triidroxieptanóico seus e análogos | |
| PT1368016E (pt) | Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac | |
| DK1613571T3 (da) | Deutererede catecholaminderivater og lægemidler indeholdende disse forbidelser | |
| BR0313665A (pt) | Utilização de bupropion para o tratamento da sìndrome das pernas inquietas | |
| BR0313230A (pt) | Uso de carboxamidas para o tratamento de tinido | |
| PT1399142E (pt) | Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2 | |
| BR0309684A (pt) | O tratamento de dor com ifendropil | |
| ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
| SE0300535D0 (sv) | Treatment of burns | |
| FI20030379A0 (fi) | Uusi farmaseuttinen koostumus |